CCIA
ADMA icon

Campbell & Co Investment Adviser’s ADMA Biologics ADMA Stock Holding History

Campbell & Co Investment Adviser’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.88M Buy
224,040
+86,572
+63% +$789K 0.1% 340
2026
Q1 		$1.24M Buy
+137,468
New +$2.17M 0.07% 436
2025
Q4 		– Sell
-64,535
Closed -$946K – 1102
2025
Q3 		$946K Buy
+64,535
New +$1.11M 0.07% 438
2025
Q2 		– Sell
-89,844
Closed -$1.78M – 1109
2025
Q1 		$1.78M Buy
89,844
+44,957
+100% +$778K 0.14% 228
2024
Q4 		$770K Sell
44,887
-13,923
-24% -$262K 0.06% 499
2024
Q3 		$1.18M Sell
58,810
-75,848
-56% -$1.18M 0.09% 378
2024
Q2 		$1.51M Sell
134,658
-97,461
-42% -$818K 0.13% 238
2024
Q1 		$1.53M Buy
232,119
+88,695
+62% +$485K 0.13% 231
2023
Q4 		$648K Buy
143,424
+23,127
+19% +$85.6K 0.06% 584
2023
Q3 		$431K Buy
+120,297
New +$463K 0.05% 584

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Campbell & Co Investment Adviser's ADMA Position: Q2 2026 in Review

Campbell & Co Investment Adviser increased its ADMA Biologics (ADMA) stake by 63% in Q2 2026, buying an estimated $789K and bringing the position to 224,040 shares worth $1.88M. The position accounts for 0.1% of the portfolio, ranked #340.

Campbell & Co Investment Adviser first reported a position in ADMA in Q3 2023 and has held it in 10 quarters since. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Campbell & Co Investment Adviser held 224,040 shares of ADMA Biologics worth $1.88M as of Q2 2026.
  • Campbell & Co Investment Adviser bought 86,572 ADMA Biologics shares in Q2 2026, an estimated $789K.
  • ADMA Biologics made up 0.1% of Campbell & Co Investment Adviser's portfolio in Q2 2026, its #340 holding.
  • Campbell & Co Investment Adviser first reported a position in ADMA Biologics in Q3 2023 and has held it in 10 quarters since.
  • 322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2026, filed 3 Aug 2026.